gimli
GKSL stock analysis context

GUJARAT KIDNEY N SUP SP L Stock Context for AI Screening

GUJARAT KIDNEY N SUP SP L is a small-cap stock in Healthcare. This page summarizes key screening signals for GUJARAT KIDNEY N SUP SP L, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.

Open interactive GKSL stock page
Price
₹132.58
1W return
-5.90%
1M return
+5.88%
3M return
+20.09%
6M return
n/a
1Y return
n/a
Market cap
₹1,045.30 cr
PE
52.66
PB
21.64
ROE
n/a
ROCE
n/a
RSI
50.25
Turnover
₹2.12 cr

Why it can matter in screens

Financials and Ownership

Quarterly income statement

PeriodRevenueEBITDAPATEPS
2025-12-3123.25 cr6.96 cr2.94 cr0.52
2025-06-3031.09 cr13.66 cr7.80 cr0.99
2025-03-3189.51 cr15.26 cr6.61 crnan
2024-12-3111.79 cr4.65 cr2.50 cr0.32

Annual income statement

No recent data available.

Balance sheet

PeriodAssetsCashDebtEquity
2025-06-3099.36 cr5.47 cr21.25 cr48.31 cr
2025-03-3191.29 cr4.58 cr22.77 cr39.83 cr

Cash flow

PeriodOCFFCFCash change
2025-12-31n/an/an/a
2025-06-300.47 cr0.41 crn/a
2025-03-31n/an/an/a
2024-12-31n/an/an/a

Shareholding Trend

PeriodPromoterFII/FPIDIIMFRetailPledge
2026-03-31+71.45%+4.88%+0.56%+0.00%+23.10%+100.00%
2025-12-31+71.45%+10.47%+1.67%+0.00%+16.40%+100.00%
2025-12-29+71.45%+13.09%+7.84%+0.00%+7.62%+100.00%

Industry Peers

SymbolNameMcapPEROE1Y
SUNPHARMASUN PHARMACEUTICAL IND L429,121.06 cr40.824543+15.06%+7.26%
DIVISLABDIVI S LABORATORIES LTD174,585.42 cr68.707369+17.81%+0.71%
TORNTPHARMTORRENT PHARMACEUTICALS L147,849.87 cr68.354079+29.94%+39.35%
APOLLOHOSPAPOLLO HOSPITALS ENTER. L119,204.71 cr64.295958+23.21%+21.70%
CIPLACIPLA LTD111,088.72 cr29.624450+12.91%-6.65%
ZYDUSLIFEZYDUS LIFESCIENCES LTD108,331.15 cr21.874917+20.44%+16.21%
DRREDDYDR. REDDY S LABORATORIES105,181.70 cr24.542479+13.88%+1.20%
LUPINLUPIN LIMITED103,385.66 cr22.341869+29.22%+15.72%

Try these prompts

Related screen ideas

Data snapshot: 2026-06-03. Not investment advice.